According to a paper published in The Lancet, the second generation targeted therapy outperformed an older targeted therapy in preventing the progression of renal cell carcinoma, or kidney cancer.
RCC patients who received the second generation targeted therapy axitinib experienced a median progression free survival of 6.7 months, compared to patients who received the older targeted therapy agent sorafenib (Nexavar).
Both targeted therapies fall under the category of vascular endothelial growth factor (VEGF) receptors. This receptor is partly responsible for building blood vessels in tumors, necessary for the growth and nourishment of the tumor.
This is touted as being the first head-to-head trial pitting targeted therapies for RCC, and based on the results of this study, atixinib has been submitted to the FDA by its manufacturer, Pfizer, for market approval in treating advanced kidney cancer.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
